EORTC research on the Gastrointestinal tract focuses on expanding what we know about the genetic, epigenetic and immunologic backgrounds of gastrointestinal tumour diseases. Clinical trials in this field focus on preclinical to clinical interaction and integrating early drug development, ensuring that new aspects of tumour biology are being investigated with appropriate contemporary technology. The ultimate goal is to better inform treatment decisions by identifying patient subsets most likely to benefit from a given therapy.
Trial of preoperative therapy for gastric and esophagogastric junction adenocarcinoma. A randomized phase II/III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer.
INtegratioN of trastuzumab, with or without pertuzumab, into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL
DREAM: Diffusion-Weighted Magnetic REsonance Imaging Assessment of Liver Metastasis to Improve Surgical Planning
Open-label first line, single-arm phase II study of CisGem combined with pembrolizumab in patients with advanced or metastatic biliary tract cancer
Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (N+ and/or R1): an open label randomized controlled phase-2-study (VESTIGE)
Published joint Clinical Practice Guidelines on the management of hepatocellular carcinoma with the European Association for the Study of the Liver (EASL) More information ; More information. These define the use of surveillance, diagnosis and therapeutic strategies recommended for patients with HCC.
The CLOCC randomised controlled phase II study performed in patients with liver metastases from colorectal cancer suggests that radiofrequency ablation of liver lesions prolongs survival (Ruers T et al. J Natl Canc Inst 2017 [in press]). Based on these findings, the group is now starting a study combining this approach with immunotherapy (ILOCC study).
Long-term follow up data confirm the significant improvement in progression-free survival of perioperative chemotherapy in resectable liver metastases from colorectal cancer More information.
Institut Gustave Roussy
University Cancer Center Leipzig
The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis